Cancer Treatment Boom Fuels AstraZeneca's Surge in Sales AstraZeneca's latest financials reveal a significant shift in the pharmaceutical industry: cancer treatment is no longer a niche area but a booming market driving growth.
The British Swedish multinational reported $30. 67 billion in total revenues for the first six months of 2026, with its oncology division accounting for nearly half of sales.
Cancer treatment demand has been particularly robust, driven by medicines like Tagrisso and Imfinzi, used to treat non small cell lung cancer and bladder cancer respectively.